Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14849158 | 0.97 | CYP2C9 (0.35) | CYP2C9KCNH2UCHL1HCRTR1HCRTR2 | |
| SCHEMBL2448912 | 0.92 | CYP2C9 (0.35) | CYP2C9KCNH2UCHL1HCRTR1HCRTR2 | |
| SCHEMBL2450986 | 0.89 | CYP2C9 (0.32) | CYP2C9KCNH2PRCPBACE1 | |
| SCHEMBL12332958 | 0.88 | CYP2C9 (0.37) | CYP2C9KCNH2UCHL1HCRTR1HCRTR2 | |
| SCHEMBL14841446 | 0.88 | CYP2C9 (0.37) | CYP2C9KCNH2UCHL1HCRTR1HCRTR2 | |
| SCHEMBL14851380 | 0.88 | CYP2C9 (0.37) | CYP2C9KCNH2UCHL1HCRTR1HCRTR2 | |
| SCHEMBL14841447 | 0.88 | CYP2C9 (0.37) | CYP2C9KCNH2UCHL1HCRTR1HCRTR2 | |
| SCHEMBL2450982 | 0.86 | CYP2C9 (0.30) | CYP2C9KCNH2 | |
| SCHEMBL12332889 | 0.85 | CYP2C9 (0.33) | CYP2C9KCNH2PRCPPARP1BACE1 | |
| SCHEMBL10121574 | 0.85 | PRCP (0.36) | HCRTR1HCRTR2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779156-B2 | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2550267-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119853-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BLVRB, RRP1B, C1QBP | CYP2C9 2576/4885KCNH2 2848/4885UCHL1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.